Journal article

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Abstract:: BACKGROUND: Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity of vaccines is often worse in older adults as a result of immunosenescence. We have reported the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, in young adults, and now describe the safety and immunogenicity of t...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., Belij-Rammerstorfer, S., Berry, L., Bibi, S., Bittaye, M., Cathie, K., Chappell, H., Charlton, S., Cicconi, P., Clutterbuck, E. A., … Group, O. C. O. V. I. D. V. T. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, 396(10267), 1979–1993.

MLA Style

Ramasamy, M. N., et al. “Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): a Single-Blind, Randomised, Controlled, Phase 2/3 Trial.” Lancet, vol. 396, no. 10267, Elsevier, 2020, pp. 1979–93.

Chicago Style

Ramasamy, MN, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, DR Owens, M Voysey, et al. 2020. “Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): a Single-Blind, Randomised, Controlled, Phase 2/3 Trial.” Lancet 396 (10267): 1979–93.
Share
Print

Access Document

Files:: RamasamyetalVoR2021.pdf

(Preview, Version of record, 987.9KB, Terms of use)

Publisher copy:: 10.1016/s0140-6736(20)32466-1

Authors

+ Ramasamy, MN More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Paediatrics
Role:: Author

+ Minassian, AM More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Role:: Author

+ Ewer, KJ More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author
ORCID:: 0000-0001-9827-9836

+ Flaxman, AL More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Role:: Author

+ Folegatti, PM More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author
ORCID:: 0000-0001-5330-0240

More authors...

+ Oxford Biomedical Research Centre More from this funder

Grant:: BZR01462

+ National Institute for Health Research More from this funder

Grant:: NF-SI-0617-10036

Publisher:: Elsevier
Journal:: Lancet More from this journal
Volume:: 396
Issue:: 10267
Pages:: 1979-1993
Publication date:: 2020-11-18
Acceptance date:: 2020-11-10
DOI:: 10.1016/s0140-6736(20)32466-1
EISSN:: 1474-547X
ISSN:: 0140-6736
Pmid:: 33220855

Language:: English
Keywords:: Oxford COVID Vaccine Trial Group

FFR
Pubs id:: 1146482
Local pid:: pubs:1146482
Deposit date:: 2020-11-25

Terms of use

Copyright holder:: Ramasamy et al.
Copyright date:: 2020
Rights statement:: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Licence:: CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP